CytoDyn
Vancouver, Washington, United States · Biotechnology, Healthcare, Health Care
CytoDyn is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV. The CCR5 receptor is a protein located on the surface of various cells including white blood cells, stellate cells which produce scar tissue in the liver, cells that undergo malignant transformation,
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Vancouver, Washington, United States
- Employees
- 21
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (CYDY)
- Website
- cytodyn.com
- Company page
Recent activity at CytoDyn
- : CytoDyn Inc. Appoints Robert E. Hoffman as CEO
- : SEC 8-K (5.02): On October 16, 2026, CytoDyn Inc. appointed Robert E. Hoffman as the new Chief Executive Officer, effective October 20, 2026, following the resignation of Jacob P. Lalezari from the position of CEO on the same date. Dr. Lalezari will transition to a non-executive role as Head of Research and Translational Sciences. Mr. Hoffman, who has extensive experience in financial leadership roles in the biotechnology sector, has served as the Company’s Chief Financial Officer since May 15, 2025, and continues his duties as principal accounting officer. This management change signals a strategic shift in leadership at CytoDyn, potentially aligning with the company’s future operational and financial strategies.
- : CytoDyn Inc. has closed $16.5 million in financing to support the development of leronlimab. This funding reflects strong investor confidence in the company's clinical progress.
Employee benefit plans
CytoDyn files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
About CytoDyn: questions and answers
What does CytoDyn do?
CytoDyn is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV. The CCR5 receptor is a protein located on the surface of various cells including white blood cells, stellate cells which produce scar tissue in the liver, cells that undergo malignant transformation,
Where is CytoDyn headquartered?
CytoDyn is headquartered in Vancouver, Washington, United States.
How many employees does CytoDyn have?
CytoDyn has about 21 employees.
What is the latest news on CytoDyn?
On Oct 19, 2026, CytoDyn Inc. Appoints Robert E. Hoffman as CEO
Is CytoDyn a public company?
Yes. CytoDyn is publicly traded under the ticker CYDY.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy